Program
pimicotinib
Also written as “pimicotinib capsules”, “ABSK021” and “Pimicotinib”.
Its studies are mostly in Giant Cell Tumor of Tendon Sheath · Synovitis, Pigmented Villonodular · Neoplasms · Pancreatic Neoplasms, led by 2 companies.
Drug pagePimicotinib: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbisko Caymanits history only | 135 open or running | phase 3since Mar 13, 2023 | Nov 27, 2019 | Dec 31, 2031phase 1 · NCT04192344 |
| Merck KGaA, Darmstadt, Germany | 11 open or running | phase 2since Mar 23, 2026 | Mar 23, 2026 | Aug 22, 2028phase 2 · NCT07499362 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck KGaA, Darmstadt, Germany only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Aug 6, 2023Named pimicotinibINNProposed as its International Nonproprietary Name in WHO's List 129 · before, ABSK021
- Mar 23, 2026First study: phase 2 study in Giant Cell Tumor of Tendon SheathFirst studyNCT07499362 · 20 planned · Japan
Ahead
- Aug 22, 2028Primary completion: phase 2 study in Giant Cell Tumor of Tendon SheathNCT07499362
TargetBeta
“An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), ”NCIt, by rule
Other programs on CSF1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| axatilimabrule | Incyte | phase 3 | 12 |
| vimseltinibrule | Ono Pharmaceutical | phase 3 | 8 |
| seralutinibrule | gb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-inc | phase 3 | 8 |
| adrixetinibrule | qurient-co-ltd | phase 2 | 3 |
Studies
The one study Merck KGaA, Darmstadt, Germany leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07499362Giant Cell Tumor of Tendon Sheath · Japan | 2 | Recruiting | Aug 22, 2028 | 20 |
How it is read
Names in the registry
- “pimicotinib capsules”, 4 entries
- “ABSK021”, 3 entries
- “Pimicotinib”, 2 entries
- “Pimicotinib(ABSK021)”, 1 entry
- “Pimicotinib capsule”, 1 entry
Codes read as this program: ABSK021.
Conditions, from the studies’ own filings
- Giant Cell Tumor of Tendon Sheath, 2 studies
- Synovitis, Pigmented Villonodular, 1 study
- Neoplasms, 1 study
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.